UNASSIGNED: Many osteoporotics have comorbid @entity6 ( @entity6 ), @entity101 ( @entity101 ), and @entity2299 ( @entity2299 ). However, whether such comorbidities alter response to anti- @entity3604 treatment is unknown. We did post hoc analyses of combined data from three @entity562 Japanese phase III trials to determine whether the presence of @entity6 , @entity101 , or @entity2299 affects its efficacy and safety. Data from 885 subjects who received 48-week treatment with @entity562 were collected and combined from the three phase III trials. They were divided into two groups by the presence or absence of comorbidities: @entity6 (n  =  53) versus non- @entity6 (n  =  832); @entity101 (n  =  278) versus non- @entity101 (n  =  607); and @entity2299 (n  =  292) versus non- @entity2299 (n  =  593). @entity79 ( @entity79 ), urinary type 1 collagen N-telopeptide (uNTX), and serum bone-specific alkaline phosphatase (BAP) were measured at baseline and sequentially until 48  weeks. @entity79 or bone markers were not different between any of the two groups. Overall, @entity79 was increased by 5.52  %, and uNTX and BAP were decreased by 35.4 and 33.8  %, respectively. Some bone markers were slightly lower in @entity6 and @entity2299 subjects, but the responses to @entity562 were not significantly different. Statin users had lower uNTX and BAP, but showed no difference in the treatment response. All the other medications had no apparent effect. Adverse event incidence was marginally higher in @entity2299 compared with non- @entity2299 (Relative risk 1.06; 95  % confidence interval 1.01-1.11), but was not related to increase in any specific events. @entity562 shows consistent safety and efficacy in suppressing bone turnover and increasing @entity79 in @entity170 @entity1 with comorbid @entity6 , @entity101 , and/or @entity2299 .

Efficacy and Safety of XXXX in @entity170 Subjects with Comorbid @entity6 , @entity101 : A Post Hoc Analysis of Phase III Trials Conducted in Japan.

@entity3604 :: ('MESH:D058866', 'Disease') :: ['osteoporotic'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HT', 'hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus', 'DM'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia', 'DL'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['Bone mineral density', 'BMD'] @entity562 :: ('MESH:C073008', 'Chemical') :: ['risedronate', 'Risedronate']
@entity562 :: (MESH:C073008,Chemical) :: ['Risedronate']
